The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Open accessAbstract
The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation of new molecular tests into clinical practice will require a greater understanding of the genetic changes that drive malignancy, the assays used to measure the resulting phenotypes and genotypes, and the regulatory processes that new molecular biomarkers must face to be accepted for clinical use. To address these issues and provide an overview of current molecular testing in 6 major malignancies, including glioma, breast cancer, colon cancer, lung cancer, prostate cancer, and acute myelogenous leukemia, an NCCN Task Force was convened on the topic of evaluating the clinical utility of tumor markers in oncology. The output of this meeting, contained within this report, describes the ways biomarkers have been developed and used; defines common terminology, including prognostic, predictive, and companion diagnostic markers, and analytic validity, clinical validity, and clinical utility; and proposes the use of a combination level of evidence score to aid in the evaluation of novel biomarker tests as they arise. The current state of regulatory oversight and anticipated changes in the regulation of molecular testing are also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–230 of 230
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., & on behalf of Genomics of AML Program Project Grant (2011) · Blood · doi:10.1182/blood.v118.21.sci-31.sci-31 · Cited by 119
Burnett, A. K., Hills, R. K., Green, C. L., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D. W., Goldstone, A. H., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236588 · Cited by 118
Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 117
Viale, G., Regan, M. M., Maiorano, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6393 · Cited by 115
Scher, H. I., Heller, G., Molina, A., Kheoh, T. S., Attard, G., Moreira, J. P. T., Sandhu, S. K., Parker, C. C., Logothetis, C. J., Mccormack, R. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.lba4517 · Cited by 113
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Buckley, J. D., Ding, L., Pan, F., Cope, L., Pelloski, C. E., Diefes, K., Hoadley, K. A., Berman, B. P., Baylin, S. B., Laird, P. W., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gb7y-mv12 · Cited by 108
Self-citationWhitman, S. P., Ruppert, A. S., Marcucci, G., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069831 · Cited by 107
Self-citationvan, Dubbink, Hj, Mariê, Brandes, Aa, TAPHOORN, M. J. B., Mj, Wesseling, P., Frenay, et al. (2010) · 中国神经肿瘤杂志 · Cited by 104
Azzoli, C. G., Giaccone, G., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091065 · Cited by 98
Marchetti, A., Milella, M., Felicioni, L., Cappuzzo, F., Irtelli, L., Grammastro, M. D., Sciarrotta, M., Malatesta, S., Nuzzo, C. M. A., Finocchiaro, G., et al. (2009) · Neoplasia · doi:10.1593/neo.09814 · Cited by 97
English, D. R., Young, J. P., Simpson, J. A., Jenkins, M. A., Southey, M. C., Walsh, M. D., Buchanan, D. D., Barker, M., Haydon, A. M., Royce, S. G., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0091 · Cited by 97
Roth, A., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Archive ouverte UNIGE (University of Geneva) · Cited by 95
Core Binding Factor Acute Myeloid Leukemia
Paschka, P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.011 · Cited by 90
Bokemeyer, C., Köhne, C. H., Rougier, P. R., Stroh, C., Schlichting, M., & Cutsem, E. V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3506 · Cited by 85
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
van den Bent, M. J., Chinot, O. L., & Cairncross, J. G. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.128 · Cited by 79
Tumour markers in prostate cancer III: Biomarkers in urine
Roobol, M. J., Haese, A., & Bjartell, A. S. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.524935 · Cited by 75
de Vogel, S., Weijenberg, M. P., Herman, J. G., Wouters, K. A. D., de Goeij, A. F. P. M., van den Brandt, P. A., A, A. P. D. B., & van Engeland, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn782 · Cited by 73
Molecular Biology Underlying the Clinical Heterogeneity of Prostate Cancer: An Update
Mackinnon, A. C., Yan, B. C., Joseph, L. J., & Al‐Ahmadie, H. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.7.1033 · Cited by 57
Đačić, S. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817bf5a9 · Cited by 53
Biospecimen reporting for improved study quality (BRISQ)
Moore, H. M., Kelly, A. T., McShane, L. M., & Vaught, J. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.04.013 · Cited by 46
Tejpar, S., Bokemeyer, C., Celik, I., Schlichting, M., Sartorius, U., & Cutsem, E. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3511 · Cited by 45
Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study
Brink, M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh177 · Cited by 38
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.02.004 · Cited by 31
Predicting the future for people with lung cancer
Xie, Y., & Minna, J. D. (2008) · Nature Medicine · doi:10.1038/nm0808-812 · Cited by 31
DNA Methylation Changes in Cancer
Toyota, M., & Yamamoto, E. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-387685-0.00014-7 · Cited by 25
Venook, A. P., Niedzwiecki, D., Lopatin, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3518 · Cited by 25
Hou, H. A., Tang, J., Lin, L., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1564.1564 · Cited by 24
Medical Device Amendments of 1976
Greenberg, R. B. (1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.12.1308 · Cited by 21
Teutsch, S. M., Bradley, L., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., Dotson, W. D., Douglas, M. P., & Berg, A. O. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195398441.003.0023 · Cited by 17
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
van den Bent, M. J., Chinot, O. L., & Cairncross, J. G. (2003) · Neuro-Oncology · doi:10.1215/s1522851702000285 · Cited by 8
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Self-citationFusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310101 · Cited by 1,080
Self-citationBidard, F.-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70069-5 · Cited by 838
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695
Metadata
- Authors
- Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., Pao, W., Sgroi, D. C., & Birkeland, M. L.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2011-11
- Volume
- 9
- Issue
- Suppl_5
- Pages
- S-1-S-32
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2236134270
- Cited by
- 255
- References
- 230
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.